CTKB
Cytek Biosciences Inc
5.90$
+1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 81.3% | 79.3% | 79.0% | 79.4% | 79.4% | 79.4% | 78.8% | 77.6% | 78.5% | 84.9% | 84.5% | 84.6% | |
| 31.5% | 33.8% | 34.3% | 36.8% | 33.0% | 19.8% | 19.7% | 15.3% | 18.8% | 19.7% | 14.6% | 16.5% | |
| 55.4% | 53.1% | 54.9% | 57.3% | 56.5% | 55.6% | 55.0% | 53.1% | 52.9% | 56.7% | 58.4% | 58.6% | |
| 11.1% | 11.3% | 10.2% | 9.3% | 10.7% | 12.1% | 11.4% | 11.5% | 12.5% | 15.6% | 12.6% | 11.5% | |
| 12.9% | 12.3% | 11.1% | 10.4% | 9.5% | 8.8% | 9.4% | 10.0% | 10.4% | 10.5% | 11.1% | 11.7% | |
| 3.2% | 3.3% | 3.3% | 3.3% | 3.3% | 3.3% | 3.5% | 3.4% | 3.4% | 3.6% | 3.7% | 3.7% | |
| 4.7% | 4.7% | 4.5% | 4.4% | 4.2% | 4.0% | 4.0% | 3.8% | 3.6% | 3.6% | 3.5% | 3.3% | |
| 20.0% | 20.5% | 20.2% | 19.6% | 21.5% | 20.8% | 21.3% | 23.5% | 23.5% | 26.0% | 27.0% | 28.0% | |
| 11.3% | 11.4% | 11.3% | 10.8% | 12.8% | 13.5% | 14.0% | 14.9% | 15.2% | 16.9% | 18.0% | 18.9% | |
| 0.7% | 0.6% | 0.9% | 0.9% | 1.1% | 1.7% | 1.6% | 1.8% | 2.6% | 2.0% | 3.5% | 2.8% | |
| 0.9% | 0.6% | 0.8% | 0.7% | 1.1% | 1.1% | 1.3% | 1.4% | 1.5% | 1.4% | 1.5% | 1.9% | |
| 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | |
| 80.0% | 79.5% | 79.8% | 80.4% | 78.5% | 79.2% | 78.7% | 76.5% | 76.5% | 74.0% | 73.0% | 72.0% | |
| -6.7% | -5.9% | -7.2% | -9.5% | -9.1% | -7.0% | -9.7% | -10.6% | -11.7% | -22.0% | -26.9% | -29.7% | |
| 26.2% | 26.4% | 26.6% | 27.2% | 27.0% | 25.9% | 26.6% | 25.7% | 25.8% | 27.8% | 28.7% | 29.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.